Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
Zink
Mathias
M
Knopf
Udo
U
Kuwilsky
Anna
A
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068180:Aripiprazole; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D011569:Psychiatric Status Rating Scales; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects; D012563:Schizophrenia, Paranoid / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D017374:Paroxetine; D000068180:Aripiprazole; D003024:Clozapine